FilingSEC EDGAR8-K
Apimeds Pharmaceuticals US Enters into Amendment to Settlement Agreement Regarding Board Composition
· SEC accepted
StageManagement and Board Composition
Filing content
Apimeds Pharmaceuticals US amended its settlement agreement to restructure its board of directors and appointed Co-CEO Sungjoon Chae to the board.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…